False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients.
Fiche publication
Date publication
août 2016
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Cohen M, De Sèze J, Marignier R, Lebrun C
Lien Pubmed
Résumé
Neuromyelitis optica spectrum disorders (NMOSD) represent a differential diagnosis of multiple sclerosis (MS). Detection of anti-aquaporin-4 antibodies (AQP4-Ab) is the strongest argument to confirm NMOSD. Diagnosing NMOSD is a major concern because specific MS disease modifying drugs can lead to neurological worsening.
Mots clés
Adult, Aquaporin 4, immunology, Autoantibodies, blood, Autoimmunity, Biomarkers, blood, False Positive Reactions, Female, Humans, Immunosuppressive Agents, adverse effects, Male, Multiple Sclerosis, blood, Natalizumab, adverse effects, Predictive Value of Tests, Retrospective Studies, Serologic Tests, Time Factors, Treatment Outcome, Young Adult
Référence
Mult. Scler.. 2016 08;22(9):1231-4